secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fusion Pharmaceuticals Inc. (—)
CIK:        0001805890
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001193125-24-154275
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.01, 5.01, 3.01, 3.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fusion Pharmaceuticals acquired by AstraZeneca for $21/share + $3 CVR, total ~$2.4B
--------------------------------------------------------------------------------

- Each Fusion share exchanged for $21.00 cash plus a contingent value right of up to $3.00 per share upon a regulatory milestone by Aug 31, 2029.
- Total transaction value approximately $2.4 billion; AstraZeneca also acquired Fusion's $211M cash balance.
- Fusion becomes wholly owned indirect subsidiary of AstraZeneca; shares to be delisted from Nasdaq and deregistered.
- CEO John F. Valliant and all prior directors resigned; Denise Lacombe, David E. White, Kevin Durning appointed as new directors.
- Former CFO John Crowley and President Mohit Rawat ceased as executive officers effective June 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1805890/000119312524154275/0001193125-24-154275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1805890/000119312524154275/d827973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-154275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer